Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.

Brachytherapy High-dose-rate Multiparametric magnetic-resonance-imaging Prostate cancer

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
22 Nov 2023
Historique:
received: 24 07 2023
revised: 08 11 2023
accepted: 10 11 2023
pubmed: 24 11 2023
medline: 24 11 2023
entrez: 23 11 2023
Statut: aheadofprint

Résumé

To evaluate the predictive factors for biochemical failure and distant metastases in a prospective cohort of patients with localized prostate cancer treated with the combination of HDR BT and EBRT. Patients with intermediate (IR) or high-risk (HR) prostate adenocarcinoma received a single fraction of HDR of 15 Gy combined with RT of 37.5 Gy in 15 fractions. ADT duration was used depending on risk-group. Descriptive analyses were performed. Univariate and multivariate Hazard Ratios were obtained. Finally, the Kaplan-Meier model was used to describe the survival of the events of interest. 309 patients were treated prospectively (199 were IR and 110 HR). Median age was 72 years; 58.3 % were MRI stage ≤ T2c, 34.1 % T3a and 7.6 % T3b; ISUP-grade 1-3 in 78.9 % and ISUP 4-5 in 21.1 %. 71.8 % of patients had ≤ 50 % positive-cores in biopsy and 28.2 % had > 50 %. Median pre-treatment PSA was 9.9 ng/mL. After a median follow-up of 88 months, 41 patients presented biochemical failure and 18 developed distant metastases. Multivariate cox-regression analyses found that MR-T3b Stage (HR 3.88, p = 0.001) and ADT use (HR 3.99, p = 0.03) were the only predictive factors for biochemical failure and the number of positive cores (>50 %) the only independent predictive factor of distant metastases (HR 4.36, p = 0.002). Patients with mpMRI evidence of invasion of the SV and involvement of more than 50% of the cores in the prostate biopsy are patients with a higher risk of presenting a biochemical recurrence or developing metastasis due to their prostate cancer, respectively.

Identifiants

pubmed: 37995851
pii: S0167-8140(23)09331-3
doi: 10.1016/j.radonc.2023.110024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110024

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

A Gomez-Iturriaga (A)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain. Electronic address: agomeziturriaga@gmail.com.

L Zaragoza (L)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

I Valverde (I)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

F Perez Azorin (F)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

B Santos-Zorrozua (B)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Clinical Epidemiology Unit, Barakaldo, Spain.

J A Guerrero (JA)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

F Couñago (F)

San Francisco de Asís Hospital, La Milagrosa Hospital, National Chair of Research and Clinical Trials, Genesis Care, Spain.

J Cacicedo (J)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

M Marban (M)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

S Santana (S)

Hospital Universitario Puerta de Hierro, Radiation Oncology, Madrid, Spain.

C Mascarell (C)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

E Novo (E)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Medical Oncology, Barakaldo, Spain.

R Fernandez (R)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Medical Oncology, Barakaldo, Spain.

J Garcia-Olaverri (J)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Urology, Barakaldo, Spain.

A Urresola (A)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiology, Barakaldo, Spain.

A Ezquerro (A)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiology, Barakaldo, Spain.

D Büchser (D)

Hospital Universitario Cruces/ Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.

Classifications MeSH